Lucie Chevillard

Lucie Chevillard

Auto-generated profile, based on publicly available information

Lucie Chevillard

Inserm, UMRS-1144, Université Paris Cité, F-75006 Paris, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2009 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
NTNicolas Tournier
Nicolas Tournier
LCLucie Chevillard
Lucie Chevillard
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane
SPStéphane Pirnay
Stéphane Pirnay
JSJean-Michel Scherrmann
Jean-Michel Scherrmann
XDXavier DECLEVES
Xavier DECLEVES
Drug interaction with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) may influence its tissue disposition including blood–brain bar

1 December 2013 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane
LCLucie Chevillard
Lucie Chevillard

Verified
Journal Article
Open access
PDF file
SLSébastien Larréché
Sébastien Larréché
Jean-Philippe ChippauxJean-Philippe Chippaux
Jean-Philippe Chippaux
LCLucie Chevillard
Lucie Chevillard
SMSimon Mathé
Simon Mathé
DRDabor Resiere
Dabor Resiere
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane
Toxins from Bothrops venoms targeting hemostasis are responsible for a broad range of clinical and biological syndromes including local and systemic bleeding, incoagulability, thrombotic microangiopathy and macrothrombosis. Beyond hemostais disorders, toxins are also involved in the pathogenesis of edema and in most complications such as hypovolemia, cardiovascular collapse, acute kidney injury, myonecrosis, compartmental syndrome and superinfection. These toxins can be classified as enzymatic proteins (snake venom metalloproteinases, snake venom serine proteases, phospholipases A2 and L-amino acid oxidases) and non-enzymatic proteins (desintegrins and C-type lectin proteins). Bleeding is due to a multifocal toxicity targeting vessels, platelets and coagulation factors. Vessel damage due to the degradation of basement membrane and the subsequent disruption of endothelial cell integrity under hydrostatic pressure and tangential shear stress is primarily responsible for bleeding. Hemorrhage is promoted by thrombocytopenia, platelet hypoaggregation, consumption coagulopathy and fibrin(ogen)olysis. Onset of thrombotic microangiopathy is probably due to the switch of endothelium to a prothrombotic phenotype with overexpression of tissue factor and other pro-aggregating biomarkers in association with activation of platelets and coagulation. Thrombosis involving large-caliber vessels in B. lanceolatus envenomation remains a unique entity, which exact pathophysiology remains poorly understood.

1 June 2010 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane
ABAnne Buisine
Anne Buisine
FJFrédéric Jacobs
Frédéric Jacobs
DRDabor Résière
Dabor Résière
LCLucie Chevillard
Lucie Chevillard
FBFrédéric J. Baud
Frédéric J. Baud

3 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KJKarim Jaffal
Karim Jaffal
LCLucie Chevillard
Lucie Chevillard
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane
Biodetoxification using intravenous lipid emulsion (ILE) in acute poisoning is of growing interest. As well as for local anesthetics, ILE is currently used to reverse toxicity caused by a broad-spectrum of lipophilic drugs. Both pharmacokinetic and pharmacodynamic mechanisms have been postulated to explain its possible benefits, mainly combining a scavenging effect called “lipid sink” and cardiotonic activity. Additional mechanisms based on ILE-attributed vasoactive and cytoprotective properties are still under investigation. Here, we present a narrative review on lipid resuscitation, focusing on the recent literature with advances in understanding ILE-attributed mechanisms of action and evaluating the evidence supporting ILE administration that enabled the international recommendations. Many practical aspects are still controversial, including the optimal dose, the optimal administration timing, and the optimal duration of infusion for clinical efficacy, as well as the threshold dose for adverse effects. Present evidence supports the use of ILE as first-line therapy to reverse local anesthetic-related systemic toxicity and as adjunct therapy in lipophilic non-local anesthetic drug overdoses refractory to well-established antidotes and supportive care. However, the level of evidence is low to very low, as for most other commonly used antidotes. Our review presents the internationally accepted recommendations according to the clinical poisoning scenario and provides the precautions of use to optimize the expected efficacy of ILE and limit the inconveniences of its futile administration. Based on their absorptive properties, the next generation of scavenging agents is additionally presented. Although emerging research shows great potential, several challenges need to be overcome before parenteral detoxifying agents could be considered as an established treatment for severe poisonings.

1 November 2016 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
CLCamille Lagard
Camille Lagard
LCLucie Chevillard
Lucie Chevillard
IMIsabelle Malissin
Isabelle Malissin
PRPatricia Risède
Patricia Risède
JCjacques CALLEBERT
jacques CALLEBERT
Bruno MégarbaneBruno Mégarbane
Bruno Mégarbane